Biotech Pushes Forward Disease Treatment Potential of Non-Psychoactive Cannabinoids - From Cashinbis

Biotech Pushes Forward Disease Treatment Potential of Non-Psychoactive Cannabinoids - From Cashinbis
Biotech Pushes Forward Disease Treatment Potential of Non-Psychoactive Cannabinoids - From Cashinbis

FROM CASHINBIS: 

There’s a global trend to prioritize research on cannabinoid medicines, and InMed Pharmaceuticals is leading the pack. By producing cannabinoids in a bacterial biosynthesis system, this pre-clinical stage biopharmaceutical company is developing therapies for multiple diseases, including Epidermolysis Bullosa, Glaucoma, and Pain.

InMed‘s pharmaceutical research is coupled with innovative drug delivery systems that have a futuristic feel – recently, the company announced success in creating topical eye drop that forms a “gel-like” lens over the eye, promoting extended absorption through the eye.

InMed’s commitment to treat the previously-thought-untreatable caught the attention of President and CEO Eric Adams, first as an investor, then as an executive.

“InMed takes medicinal marijuana to a completely new level, that of true pharmaceutical drug development. We don’t grow any plants, and you don’t smoke any of our products,” Adams said



READ FULL INTERVIEW AND STORY AT CASHINBIS

 

Thumbnail Photo Credit: N/A by N/A is licensed under N/A N/A